BACKGROUND: The diagnosis of Parkinson's disease remains a challenge in patients who have abnormal symptoms or show a lack of response to medication. The imaging technique, DaTscan, can be used to visualize dopamine degeneration in the nigro-striatum, which is associated with Parkinsonian Syndrome. We examined the use of the DaTscan in diagnosis, confidence in diagnosis, and clinical management. METHODS: Physicians of 125 patients were contacted to fill out a brief survey about changes in diagnosis, confidence of diagnosis, and clinical management after assessment with the DaTscan. RESULTS: There was an overall increase in confidence of diagnosis with the results of the DaTscan. Physicians also stated that the DaTscan impacted their diagnosis in 68% of the patients, as well as an impact in the clinical management of 58% of the patients. CONCLUSION: The DaTsan can be used as a tool to help diagnose Parkinsonian Syndrome in patients with unclear symptoms.
BACKGROUND: The diagnosis of Parkinson's disease remains a challenge in patients who have abnormal symptoms or show a lack of response to medication. The imaging technique, DaTscan, can be used to visualize dopamine degeneration in the nigro-striatum, which is associated with Parkinsonian Syndrome. We examined the use of the DaTscan in diagnosis, confidence in diagnosis, and clinical management. METHODS: Physicians of 125 patients were contacted to fill out a brief survey about changes in diagnosis, confidence of diagnosis, and clinical management after assessment with the DaTscan. RESULTS: There was an overall increase in confidence of diagnosis with the results of the DaTscan. Physicians also stated that the DaTscan impacted their diagnosis in 68% of the patients, as well as an impact in the clinical management of 58% of the patients. CONCLUSION: The DaTsan can be used as a tool to help diagnose Parkinsonian Syndrome in patients with unclear symptoms.
Authors: T S Benamer; J Patterson; D G Grosset; J Booij; K de Bruin; E van Royen; J D Speelman; M H Horstink; H J Sips; R A Dierckx; J Versijpt; D Decoo; C Van Der Linden; D M Hadley; M Doder; A J Lees; D C Costa; S Gacinovic; W H Oertel; O Pogarell; H Hoeffken; K Joseph; K Tatsch; J Schwarz; V Ries Journal: Mov Disord Date: 2000-05 Impact factor: 10.338
Authors: Hani T S Benamer; Wolfgang H Oertel; Jim Patterson; Donald M Hadley; Oliver Pogarell; H Höffken; A Gerstner; Donald G Grosset Journal: Mov Disord Date: 2003-09 Impact factor: 10.338
Authors: Andreas Kupsch; Nin Bajaj; Frederick Weiland; Antonio Tartaglione; Susanne Klutmann; Ronald Copp; Paul Sherwin; Ann Tate; Igor D Grachev Journal: Neurodegener Dis Date: 2012-05-08 Impact factor: 2.977
Authors: Zeynep Idil Seckin; Jennifer L Whitwell; Rene L Utianski; Hugo Botha; Farwa Ali; Joseph R Duffy; Heather M Clark; Mary M Machulda; Lennon G Jordan; Hoon-Ki Min; Val J Lowe; Keith A Josephs Journal: J Neurol Date: 2020-05-09 Impact factor: 4.849
Authors: Matthew F Covington; Scott Sherman; Denise Lewis; Hong Lei; Elizabeth Krupinski; Phillip H Kuo Journal: PLoS One Date: 2015-07-30 Impact factor: 3.240